文献速递泌尿生殖腹部MR

基于多参数MRI的影像组学特征用于区分惰性与侵袭性前列腺癌的开发与验证

Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer.
PubMed 文献 · Br J Radiol · 2021-09-29

研究纳入139例病理确诊的前列腺癌患者,从T2WI和DWI提取1576个影像组学特征,构建并验证区分惰性与侵袭性前列腺癌的影像组学特征。该特征在训练集AUC为0.853(95%CI 0.766-0.941),验证集AUC为0.901(95%CI 0.793-1.000),决策曲线显示阈值概率20-90%时净获益更佳。结论认为该特征有望作为治疗前无创区分工具。

要点

  • 影像组学特征可用于治疗前区分惰性与侵袭性前列腺癌。
  • 训练集AUC 0.853,验证集AUC 0.901,判别能力良好。
  • 阈值概率20-90%时决策曲线显示净获益更佳。

核心结论

  • 基于多参数MRI的影像组学特征有望作为治疗前无创区分惰性与侵袭性前列腺癌的工具,辅助个体化治疗决策。

研究设计与样本

  • 回顾性研究,共纳入139例病理确诊的前列腺癌患者,分为训练集93例和验证集46例。
  • 从每例患者的T2WI和DWI图像分别提取788个影像组学特征,共1576个。
  • 采用Select K Best和LASSO回归算法在训练集中构建影像组学特征,并在验证集中评估。
  • 以病理结果为参考标准,通过ROC曲线分析评估预测性能,并计算校准曲线和决策曲线。

诊断标准与关键数值

  • 共筛选出9个影像组学特征构成影像组学特征。
  • 影像组学评分在惰性与侵袭性前列腺癌间差异有统计学意义(p < 0.001)。
  • 训练集区分惰性与侵袭性前列腺癌的AUC为0.853(95% CI: 0.766 to 0.941)。
  • 验证集区分惰性与侵袭性前列腺癌的AUC为0.901(95% CI: 0.793 to 1.000)。
  • 决策曲线分析显示阈值概率在20%至90%范围内可获得更大的净获益。

临床应用与阅片要点

  • 治疗前可结合多参数MRI影像组学特征辅助区分惰性与侵袭性前列腺癌,为个体化治疗决策提供参考。

局限性

  • 原文未明确报告研究局限性;样本量有限(共139例),验证集仅46例,需外部验证确认泛化能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To develop and validate a non-invasive MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer (PCa) prior to therapy.

METHODS: In all, 139 qualified and pathology-confirmed PCa patients were divided into a training set (n = 93) and a validation set (n = 46). A total of 1576 radiomics features were extracted from the T2WI (n = 788) and diffusion-weighted imaging (n = 788) for each patient. The Select K Best and the least absolute shrinkage and selection operator regression algorithm were used to construct a radiomics signature in the training set. The predictive performance of the radiomics signature was assessed in the training set and then validated in the validation set by receiver operating characteristic curve analysis. We computed the calibration curve and the decision curve to evaluate the calibration and clinical usefulness of the signature.

RESULTS: Nine radiomics features were identified to form the radiomics signature. The radiomics score (Rad-score) was significantly different between indolent and aggressive PCa (p < 0.001). The radiomics signature exhibited favorable discrimination between the indolent and aggressive PCa groups in the training set (AUC: 0.853, 95% CI: 0.766 to 0.941) and validation set (AUC: 0.901, 95% CI: 0.793 to 1.000). The decision curve analysis showed that a greater net benefit would be obtained when the threshold probability ranged from 20 to 90%.

CONCLUSION: The multiparametric MRI-based radiomics signature can potentially serve as a non-invasive tool for distinguishing between indolent and aggressive PCa prior to therapy.

ADVANCES IN KNOWLEDGE: The multiparametric MRI-based radiomics signature has the potential to non-invasively distinguish between the indolent and aggressive PCa, which might aid clinicians in making personalized therapeutic decisions.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang L, Jiang D, Chen C, et al. Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer. Br J Radiol. 2021. PMID: 34289319. doi:10.1259/bjr.20210191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。